ArticleVirology journal2009
An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.
Article in Virology journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 71 citations in OpenAlex.
- Nanoparticle-Based Antigen Delivery: Advancing Immunization Strategies against Infectious Pathogens.Biomaterials research · 2026Review
- Harnessing plant chloroplasts for oral delivery of a multi-epitope HPV vaccine: toward cost-effective systemic and mucosal immunization.Journal of biological engineering · 2025Article
- Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies.Biomarker research · 2024Review
- Nanoadjuvants: Promising Bioinspired and Biomimetic Approaches in Vaccine Innovation.ACS omega · 2023Review
- Review
- Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2.Biotechnology letters · 2022Review
- Contributions of the international plant science community to the fight against human infectious diseases - part 1: epidemic and pandemic diseases.Plant biotechnology journal · 2021Review
- The Use of the Antigenic Protein HPV6 L1 to Induce the Synthesis of Interferon, CD4 and CD8 T Lymphocytes, and Granzyme B in Blood and Splenocytes of Mice in Order to Develop a Broad Vaccine against Anogenital Papillomatoses.Doklady. Biochemistry and biophysics · 2021Article
- A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections.Frontiers in pharmacology · 2021Review
- Plant Platforms for Efficient Heterologous Protein Production.Biotechnology and bioprocess engineering : BBE · 2021Review
- Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs).Vaccines · 2020Article
- Short Disordered Epitope of CRTAM Ig-Like V Domain as a Potential Target for Blocking Antibodies.International journal of molecular sciences · 2020Article
- Substitution of Human Papillomavirus Type 16 L2 Neutralizing Epitopes Into L1 Surface Loops: The Effect on Virus-Like Particle Assembly and Immunogenicity.Frontiers in plant science · 2019Article
- Therapeutic vaccines for high-risk HPV-associated diseases.Papillomavirus research (Amsterdam, Netherlands) · 2018Review
- Plant-based chimeric HPV-virus-like particles bearing amyloid-β epitopes elicit antibodies able to recognize amyloid plaques in APP-tg mouse and Alzheimer's disease brains.Inflammopharmacology · 2018Article
- Nanoparticle Vaccines Against Infectious Diseases.Frontiers in immunology · 2018Review
- Plant-based vaccines against viruses.Virology journal · 2014Review
- N-glycosylation modification of plant-derived virus-like particles: an application in vaccines.BioMed research international · 2014Review
- Virus-like particles for the prevention of human papillomavirus-associated malignancies.Expert review of vaccines · 2013Review
- Production of pharmaceutical proteins in solanaceae food crops.International journal of molecular sciences · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEven though two prophylactic vaccines against HPV are currently licensed, infections by the virus continue to be a major health problem mainly in developing countries. The cost of the vaccines limits wide-scale application in poor countries. A promising strategy for producing affordable and efficient vaccines involves the expression of recombinant immunogens in plants. Several HPV genes have been expressed in plants, including L1, which can self-assemble into virus-like particles. A plant-based, dual prophylactic/therapeutic vaccine remains an attractive possibility.
resultsWe sought to express in tomato plants chimeric HPV 16 VLPs containing L1 fused to a string of epitopes from HPV 16 E6 and E7 proteins. The L1 employed had been modified to eliminate a strong inhibitory region at the 5' end of the molecule to increase expression levels. Several tomato lines were obtained expressing either L1 alone or L1-E6/E7 from 0.05% to 0.1% of total soluble protein. Stable integration of the transgenes was verified by Southern blot. Northern and western blot revealed successful expression of the transgenes at the mRNA and protein level. The chimeric VLPs were able to assemble adequately in tomato cells. Intraperitoneal administration in mice was able to elicit both neutralizing antibodies against the viral particle and cytotoxic T-lymphocytes activity against the epitopes.
conclusionIn this work, we report for the first time the expression in plants of a chimeric particle containing the HPV 16 L1 sequence and a string of T-cell epitopes from HPV 16 E6 and E7 fused to the C-terminus. The particles were able to induce a significant antibody and cytotoxic T-lymphocytes response. Experiments in vivo are in progress to determine whether the chimeric particles are able to induce regression of disease and resolution of viral infection in mice. Chimeric particles of the type described in this work may potentially be the basis for developing prophylactic/therapeutic vaccines. The fact that they are produced in plants, may lower production costs considerably.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.